TU
TUO.F Terumo Corporation
- Market cap
- EUR 20.4B
- P/E
- 23.4x
- P/B
- 2.19x
- ROE
- 16.9%
- Dividend yield
- 1.46%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is TUO.F undervalued?
Graham numberTUO.F trades 51.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Terumo Corporation fundamental analysis
No fundamental analysis for Terumo Corporation yet.
Terumo Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Terumo Corporation
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PT…
Full company profileTerumo Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Terumo Corporation annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 514B | 588B | 599B | 629B | 614B | 703B | 820B | 922B | 1.04T | 1.13T | 1.25T |
| Gross Profit | 278B | 319B | 326B | 344B | 327B | 369B | 417B | 479B | 561B | 595B | 714B |
| Operating Income | 76.6B | 109B | 107B | 111B | 98.4B | 116B | 117B | 140B | 158B | 176B | 358B |
| EBITDA | - | 151B | 153B | 164B | 153B | 176B | 190B | 220B | 246B | 277B | 476B |
| Net Income | 54.2B | 91.3B | 79.5B | 85.2B | 77.3B | 88.8B | 89.3B | 106B | 117B | 136B | 282B |
| EPS | 77 | 129 | 107 | 113 | 102 | 117 | 120 | 72 | 79 | 92 | 191 |
| Balance Sheet | |||||||||||
| Total Assets | 1.02T | 1.08T | 1.12T | 1.24T | 1.35T | 1.47T | 1.60T | 1.83T | 1.83T | 2.31T | 2.37T |
| Total Liabilities | 532B | 529B | 423B | 486B | 495B | 461B | 491B | 504B | 460B | 728B | 712B |
| Shareholders' Equity | 489B | 550B | 698B | 755B | 857B | 1.01T | 1.11T | 1.33T | 1.37T | 1.58T | 1.66T |
| Cash & Short-term Investments | 105B | 168B | 123B | 167B | 201B | 205B | 187B | 205B | 222B | 280B | 315B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 80.9B | 115B | 93.6B | 117B | 121B | 141B | 118B | 146B | 211B | 231B | 298B |
| Capital Expenditure | 29.8B | 31.9B | 39.3B | 62.3B | 62.3B | 53.5B | 52.7B | 78.8B | 82.4B | 102B | 75.3B |
| Free Cash Flow | - | 73.2B | 39.2B | 34.0B | 38.4B | 67.4B | 45.4B | 67.6B | 128B | 129B | 223B |
| Ratios | |||||||||||
| ROE | 11.1% | 16.6% | 11.4% | 11.3% | 9.0% | 8.8% | 8.0% | 8.0% | 8.5% | 8.6% | 16.9% |
| ROA | 5.3% | 8.5% | 7.1% | 6.9% | 5.7% | 6.0% | 5.6% | 5.8% | 6.4% | 5.9% | 11.9% |
| Net Profit Margin | 10.5% | 15.5% | 13.3% | 13.5% | 12.6% | 12.6% | 10.9% | 11.5% | 11.3% | 12.0% | 22.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Terumo Corporation dividends
- Dividend yield
- 1.46%
- Forward dividend
- 0.20 EUR
- Payout ratio
- 30.4%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 41.3B | 28 | 30.4% |
| 2025 | JPY 35.6B | 24 | 30.5% |
| 2024 | JPY 32.0B | 22 | 30.1% |
| 2023 | JPY 27.9B | 37 | 31.2% |
| 2022 | JPY 23.5B | 31 | 26.4% |
| 2021 | JPY 21.2B | 28 | 27.4% |
| 2020 | EUR 20.5B | 27 | 24.1% |
| 2019 | EUR 19.6B | 26 | 24.6% |
| 2018 | EUR 15.8B | 22 | 17.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Mar 28, 2024.
Who owns Terumo Corporation
- Insiders 2.29%
- Institutions 67.96%
- Public & others 29.76%
- Shares outstanding 1.48B
- Free float 1.45B
Terumo Corporation company profile
- Company name
- Terumo Corporation
- Ticker
- TUO.F
- ISIN
- JP3546800008
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- March
- Address
- 2-44-1, Hatagaya, Shibuya, Japan, 151-0072
- Phone
- 81 3 3374 8111
- Website
- terumo.com
About Terumo Corporation
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The Terumo Organ Technologies segment provides organ preservation devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Shibuya, Japan.
Terumo Corporation management
10- Mr. Hikaru SamejimaRepresentative Director, President & CEO · born 1964
- Jin HagimotoCFO, CIO, GM of Accounting, Corporate Planning, Tax, IT Planning Dept. & GBS
- Sei DobashiExecutive Officer, COO & Medical Care Solutions
- Shinji Omori Ph.D.CTO, Corporate R&D Officer, GM of R&D Center & Executive Officer
- Ms. Miho MizuguchiExecutive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department
- Tomoko AdachiChief Human Resources Officer & Group Executive Officer
- Itaru SakaguchiGroup Managing Executive Officer
- Fumihisa HiroseGroup Managing Executive Officer
- Mr. Norimasa KunimotoDirector & Group Managing Executive Officer · born 1963
- Mr. Toshihiko OsadaGroup Senior Managing Executive Officer & Director · born 1967